These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9280254)

  • 21. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.
    Reimer P; Balzer T
    Eur Radiol; 2003 Jun; 13(6):1266-76. PubMed ID: 12764641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model.
    Kato N; Takahashi M; Tsuji T; Ihara S; Brautigam M; Miyazawa T
    Invest Radiol; 1999 Sep; 34(9):551-7. PubMed ID: 10485069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging.
    Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
    J Magn Reson Imaging; 1994; 4(3):309-14. PubMed ID: 8061426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST): New protocol infusion to improve arterial phase evaluation--a prospective study.
    Grazioli L; Bondioni MP; Romanini L; Frittoli B; Gambarini S; Donato F; Santoro L; Colagrande S
    J Magn Reson Imaging; 2009 Mar; 29(3):607-16. PubMed ID: 19243056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.
    Ward J; Naik KS; Guthrie JA; Wilson D; Robinson PJ
    Radiology; 1999 Feb; 210(2):459-66. PubMed ID: 10207430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
    Mintorovitch J; Shamsi K
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
    Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
    Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New MR contrast media in liver diagnosis. Initial clinical results with hepatobiliary Eovist (gadolinium-EOB-DTPA) and RES-specific Resovist (SH U 555 A)].
    Reimer P; Tombach B; Daldrup H; Hesse T; Sander G; Balzer T; Shamsi K; Berns T; Rummeny EJ; Peters PE
    Radiologe; 1996 Feb; 36(2):124-33. PubMed ID: 8867429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A).
    Kehagias DT; Gouliamos AD; Smyrniotis V; Vlahos LJ
    J Magn Reson Imaging; 2001 Nov; 14(5):595-601. PubMed ID: 11747012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver.
    Reimer P; Müller M; Marx C; Balzer T
    Acad Radiol; 2002 Aug; 9 Suppl 2():S336-8. PubMed ID: 12188267
    [No Abstract]   [Full Text] [Related]  

  • 33. [Overview of MRI contrast media. The case of endorem].
    Duroux M
    Radiologe; 1995 Nov; 35(11 Suppl 2):S247-8. PubMed ID: 8588029
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.
    Sharma R; Saini S; Ros PR; Hahn PF; Small WC; de Lange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK; Morris M; Lucas M
    J Magn Reson Imaging; 1999 Feb; 9(2):291-4. PubMed ID: 10077027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Focal intrahepatic siderosis, diagnostic pitfall, iatrogenic image].
    Arteaga C; Raillat A; Salamand P; Debonne JM; Bonnet D; Martet G; Veuillet MO; Battini-Nouzille A; Briant JF
    J Radiol; 1998 Feb; 79(2):157-8. PubMed ID: 9757234
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging.
    Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Hatanaka Y; Murakami R; Nishiharu T; Takahashi M; Higashida Y; Moribe N
    Radiology; 1995 Apr; 195(1):106-12. PubMed ID: 7892448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of ferucarbotran in MR imaging of the liver: a pre- and postexamination questionnaire-based multicenter investigation.
    Onishi H; Murakami T; Kim T; Hori M; Hirohashi S; Matsuki M; Narumi Y; Imai Y; Sakurai K; Nakamura H
    J Magn Reson Imaging; 2009 Jan; 29(1):106-11. PubMed ID: 19097079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227.
    Harisinghani MG; Saini S; Weissleder R; Halpern EF; Schima W; Rubin DL; Stillman AE; Sica GT; Small WC; Hahn PF
    Radiology; 1997 Mar; 202(3):687-91. PubMed ID: 9051017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection and segmental location of malignant hepatic tumors: comparison of ferumoxides-enhanced gradient-echo and T2-weighted spin-echo MR imaging.
    Van Beers BE; Lacrosse M; Jamart J; Grandin C; Gigot JF; Horsmans Y; Demeure R; Pringot J
    AJR Am J Roentgenol; 1997 Mar; 168(3):713-7. PubMed ID: 9057521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.